Type 2 dıabetes mellıtus and CA 19-9 levels

Uygur-Bayramiçli, Oya; Dabak, Reşat; Orbay, Ekrem; Dolapcioglu, Can; Sargın, Mehmet; Kilicoglu, Gamze; Güleryüzlü, Yüksel; Mayadağlı, Alpaslan

doi:10.3748/wjg.v13.i40.5357

Cited by 66 publications

(57 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, CA 19-9 in diabetics may be considered as the indication of exocrine pancreatic dysfunction and a higher cut-off value of CA 19-9 was proposed to differentiate benign and malignant pancreatic disease (38). Abdominal US would likewise be an ideal method for screening: it is easy to carry out, widely available and cost-effective (42).…”

Section: Discussionmentioning

confidence: 99%

New-onset type 2 diabetes mellitus – A high-risk group suitable for the screening of pancreatic cancer?

et al. 2016

View full text Add to dashboard Cite

2Background: Type 2 diabetes mellitus is widely considered to be associated with pancreatic cancer.Objective: To determine the incidence of pancreatic cancer in new-onset type 2 diabetic patients by measuring the serum level of CA 19-9 and performing abdominal ultrasonography (US). Patients and Methods:Consecutive type 2 diabetic patients in whom diabetes was diagnosed within 36 months were included in this prospective study. Serum CA 19-9 measurement and US were performed in all patients. If any of two was positive, abdominal computer tomography (CT) was carried out. Endoscopic ultrasound-guided fine needle aspiration or direct surgical referral was performed on patients with CT-identified lesions.Results: A total of 115 patients were enrolled. CA 19-9 was elevated in 10 patients but pancreatic cancer diagnosed in neither of them. Pancreatic cancer was revealed by morphological means in three patients without elevated CA 19-9 level. The sensitivity, specificity, positive-, negative predictive values and validity were 0%, 90.4%, 0%, 97.9% and 87.9% for CA 19-9, 66.7%, 100%, 100%, 99% and 99% for US, respectively. The value of the Standardized Incidence Ratio for pancreatic cancer in new-onset type-2 diabetic patients was 198.6 (95% CI=6.25-46.9). Conclusions:The prevalence of pancreatic cancer in patients with new-onset type-2 diabetes is significantly higher than that in the general population and screening is beneficial for detecting PaC in this patient population. CA 19-9 and US is not reliable screening modality for pancreatic cancer screening in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

New-onset type 2 diabetes mellitus – A high-risk group suitable for the screening of pancreatic cancer?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Some reports indicate increased CA 19-9 in patients with diabetes (24,25). In addition, a corresponding change in CA 19-9 with HbA 1c in patients with diabetes has also been reported (26).…”

Section: Discussionmentioning

confidence: 99%

Increased CA 19-9 level in patients without malignant disease

Kim

Lee

Kim

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: The measurement of carbohydrate antigen 19-9 (CA 19-9) is recommended for the diagnosis and follow-up of pancreatic cancer. However, increased CA 19-9 has also been reported in patients with various benign diseases of the lung. We aimed to elucidate the pulmonary radiographic abnormalities and laboratory results associated with increased concentrations of CA 19-9. Methods: This study was performed using a case-controlled design. Cases included all participants in a cancer screening program who had an increased CA 19-9 concentration ()37 U/mL), but without a diagnosis of malignancy. Age-and sex-matched participants with normal CA 19-9 levels were enrolled as controls. Laboratory results and radiographic features were compared. Results: In total, 119 participants with increased CA 19-9 concentrations and 476 controls were included. A higher erythrocyte sedimentation rate (ESR) wadjusted odd ratio (aOR), 1.03; 95% confidence interval (CI), 1.01-1.05x, higher hemoglobin A 1c (HbA 1c

show abstract

“…Unfortunately, studies have shown that serum CA19-9 levels are also elevated in a broad range of benign and malignant conditions including cholecystitis, choledocholithiasis, hepatitis, cirrhosis, pancreatitis, achalasia, inflammatory bowel disease, rheumatoid arthritis, heavy tea consumption, Sjögren's syndrome, Hashimoto's thyroiditis, cholangiocarcinoma, and colorectal, hepatocellular, esophageal, lung, and ovarian carcinomas [6,7].…”

Section: Introductionmentioning

confidence: 99%